Gastro-oesophageal reflux, medical resource utilization and upper gastrointestinal endoscopy in patients at risk of oesophageal adenocarcinoma

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2008, Pages 137-143

  Van Soest, E M ^a   Dieleman, J P ^a   Sturkenboom, M C J M ^a   Siersema, P D ^a   Kuipers, E J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; RESOURCE ALLOCATION; RISK FACTORS; SURVIVAL RATE;

EID: 44649100138     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03693.x     Document Type: Article

References (20)

1. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinoma in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998 7 : 749 56.
2. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999 94 : 86 91.
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998 83 : 2049 53.
4. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 825 31.
5. Solaymani-Dodaran M, Logan RFA, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004 53 : 1070 4.
6. Van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MCJM, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005 54 : 1062 6.
7. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007 5 : 17 26.
8. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004 39 : 1175 9.
9. Anonymous. Multidisciplinaire richtlijn Maagklachten. Utrecht : Kwaliteitsinstituut voor de gezondheidszorg CBO en Nederlands Huisartsen Genootschap (NHG), 2004.
10. Anonymous. American Gastroenterology Association medical position statement and technical review. Evaluation of dyspepsia. Gastroenterology 1998 114 : 579 95.
11. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003 98 : 1627 33.
12. Wani S, Sharma P. The rationale for screening and surveillance of Barrett's metaplasia. Best Pract Res Clin Gastroenterol 2006 20 : 829 42.
13. Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002 97 : 1888 95.
14. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 199 211.
15. Lassen A, Hallas J, de Muckadell OB. The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication. Gastroenterology 2005 129 : 1179 86.
16. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992 9 : 330 9.
17. Vlug AE, van der Lei J, Mosseveld BMT, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999 38 : 339 44.
18. Loffeld RJLF. Gastro-oesophageal reflux disease - experience in daily practice: Symptoms and symptom assessment. Scand J Gastroenterol 2006 243 : 3 6.
19. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002 122 : 26 33.
20. Yalamarthi S, Witherspoon P, McCole D, Auld CD. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 2004 36 : 874 9.